What are the actionable interfaces between NGS-based whole exome profiling and immunotherapy, focusing on new data on tumor mutational burden, microsatellite instability (MSI), and related signatures?

What are the actionable interfaces between NGS-based whole exome profiling and immunotherapy, focusing on new data on tumor mutational burden, microsatellite instability (MSI), and related signatures?

What are the current actionable interfaces between NGS-based whole exome profiling and immunotherapy, focusing on new data related to tumor mutational burden, microsatellite instability (MSI), and related signatures?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Samuel Klempner, MD

Samuel Klempner, MD

Director of Precision Medicine
The Angeles Clinic and Research Institute
Cedars-Sinai Medical Center
Los Angeles, CA